Ascendis Pharma A/S (NASDAQ:ASND) Coverage Initiated at Royal Bank of Canada

Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a report issued on Wednesday, MarketBeat Ratings reports. The firm set an "outperform" rating and a $205.00 price target on the biotechnology company's stock. Royal Bank of Canada's price target indicates a potential upside of 28.15% from the stock's previous close.

Several other research firms also recently weighed in on ASND. UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective for the company. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Evercore ISI increased their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald increased their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Stock Down 3.1 %

NASDAQ:ASND traded down $5.08 during mid-day trading on Wednesday, reaching $159.97. 380,651 shares of the stock were exchanged, compared to its average volume of 481,469. The company has a 50 day simple moving average of $152.00 and a 200-day simple moving average of $138.12. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The stock has a market capitalization of $9.75 billion, a P/E ratio of -22.53 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the company. Harbor Capital Advisors Inc. increased its holdings in shares of Ascendis Pharma A/S by 1.3% during the first quarter. Harbor Capital Advisors Inc. now owns 85,960 shares of the biotechnology company's stock valued at $13,398,000 after purchasing an additional 1,087 shares during the period. Toth Financial Advisory Corp acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $832,000. GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 15,593.0% during the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock valued at $142,600,000 after buying an additional 90,907 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $174,000. Finally, Woodline Partners LP raised its position in Ascendis Pharma A/S by 35.2% during the fourth quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company's stock valued at $43,730,000 after buying an additional 82,624 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.